Medgenics (MDGN -1.2%) says it's received a Notice of Allowance from the Japanese Patent and...

|About: Medgenics (MDGN)|By:, SA News Editor

Medgenics (MDGN -1.2%) says it's received a Notice of Allowance from the Japanese Patent and Trademark Office for key claims protecting the use of it's Infradure Biopump technology. The technology provides interferon therapy for the treatment of hepatitis B, C, and D. MDGN has already been granted patents covering core Biopump technology in the U.S. and in the EU.